Quantification of the clusters within the three cohorts demonstrated frequencies of CD32+CD154+ and TLR2+TLR4+ significantly increased in psoriasis patients compared to healthy controls (p = 0.048 and p = 0.049, respectively) at baseline, as well as GARP+P2Y12+ after four weeks of therapy (p = 0.042; Fig. 2b). The gene discussed is TLR2; the disease is psoriasis.